Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Saved in:
| Title: | Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. |
|---|---|
| Authors: | Hayes TK; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA.; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA., Aquilanti E; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Persky NS; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA.; Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA.; Aera Therapeutics, Cambridge, MA, USA., Yang X; Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Kim EE; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA., Brenan L; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Goodale AB; Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Alan D; Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Sharpe T; Data Science Platform, The Broad Institute of M.I.T. and Harvard Cambridge, Cambridge, MA, USA., Shue RE; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Westlake L; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Golomb L; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Silverman BR; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA., Morris MD; Summer Honors Undergraduate Research Program, Harvard Medical School, Boston, MA, USA., Fisher TR; Summer Honors Undergraduate Research Program, Harvard Medical School, Boston, MA, USA., Beyene E; Summer Honors Undergraduate Research Program, Harvard Medical School, Boston, MA, USA., Li YY; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Cherniack AD; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Piccioni F; Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA.; Merck Research Laboratories, Cambridge, MA, USA., Hicks JK; Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Chi AS; Center for Neuro-Oncology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA., Cahill DP; Center for Neuro-Oncology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA., Dietrich J; Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA., Batchelor TT; Department of Neurology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA., Root DE; Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA., Johannessen CM; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA.; Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Meyerson M; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA. matthew_meyerson@dfci.harvard.edu.; Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA, USA. matthew_meyerson@dfci.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2024 Mar 28; Vol. 15 (1), pp. 2742. Date of Electronic Publication: 2024 Mar 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-45594-4 |
